The United States Federal Drug Administration (FDA) has found that breast implant patients have an increased risk of developing a type of cancer called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
BIA-ALCL is not breast cancer. When breast implants are placed in the body, they are inserted behind the breast tissue or under the chest muscle. Over time, a fibrous scar called a capsule develops around the implant, separating it from the rest of the breast. In women with breast implants, the ALCL was generally found adjacent to the implant itself and contained within the fibrous capsule. ALCL is lymphoma, a type of cancer involving cells of the immune system. It is not cancer of the breast tissue.
Most patients suffering from BIA-ALCL are diagnosed when they seek medical treatment for implant-related symptoms such as pain, lumps, swelling, or asymmetry that developed after their initial surgical sites were fully healed. These symptoms are due to collection of fluid (persistent seroma), hardening of breast area around the implant (capsular contracture), or masses surrounding the breast implant. Typically, examination of the fluid and capsule surrounding the breast implant leads to the ALCL diagnosis.
Claims have been filed nationwide against various manufacturers and distributors of breast implants, including Allergan, Mentor, and Sientra.
Did you have breast implant surgery? Were you diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)? Speak with our breast implant litigation attorneys today for a free consultation.
The United States Federal Drug Administration (FDA) first identified a possible association between breast implants and the development of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) back in 2011. Since that time, research has shown that it does not matter whether the breast implants are silicone gel or saline. It also does not matter whether the breast implants were textured or smooth surface, although findings suggests that the textured variety have led to the condition far more often. It also does not matter whether the implants were cosmetic or reconstructive, and it can take several years for BIA-ALCL to develop.
In addition, similar claims have been found in patients using textured tissue expanders. A tissue expander is used stretch skin and other tissues before breast reconstruction after mastectomy, correction of an underdeveloped breast, scar revision, and tissue defect procedures. It is a temporary implant, placed under the breast skin or muscles of the chest to stretch skin and other tissues, and is intended to be replaced with a breast implant at a later time.
If you have had breast implant or tissue expansion surgery and have been diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), you may be entitled to compensation.
Please contact Stark & Stark to speak with one of the defective breast implant cancer attorneys, free of charge, who can help assess any claims that you may have and to help you understand the defective breast implant settlement and lawsuit process. We are a large, experienced law firm that specializes in defective breast implant settlements, including Allergan lawsuits. Allow us to help you today.
Stark & Stark is committed to holding drug and medical device manufacturers liable when their products improperly endanger the public. Stark & Stark attorneys are actively filing lawsuits and seeking settlements on behalf of defective breast implant patients diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
The attorneys of Stark & Stark’s Mass Tort and Class Action Team have successfully represented thousands of clients throughout the nation. We are not a marketing company. We are an 80-year-old law firm of over 100 experienced attorneys. Let us work for you.
Please contact Stark & Stark to speak with one of our defective breast implant attorneys, free of charge, who can help assess any claims that you may have and to help you understand the defective breast implant settlement and BIA-ALCL lawsuit process. As with any lawsuit, there are applicable statutes of limitation and repose, so do not wait. Allow us to help you today.
Allergan is the primary manufacturer in this litigation. Allergan produced textured breast implants and textured tissue expanders under different brand names, including Biocell, Natrelle and McGhan. Textured implants and expanders were originally thought to reduce the risk of movement within the body; however, textured breast implants and textured tissue expanders have now been associated with a heightened risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This led the United States Federal Drug Administration (FDA) to demand that Allergan recall the following products:
Claims against Allergan have been filed across the nation, alleging that Allergan new or should have known of the dangers that its recalled products posed to patients, and that Allergan failed to warn the patients of those dangers. Currently, all of those claims are being sought to be consolidated in a Multidistrict Litigation (“MDL”).
The Allergan textured breast implant and textured tissue expander attorneys at Stark & Stark are actively negotiating settlements and filing additional lawsuits on behalf of patients injured or killed from the use of these defective products. Our lawyers are experienced in mass torts MDL litigation cases and in negotiating with medical device and pharmaceutical settlement representatives. If you or someone you love has suffered an injury from a recalled Allergan textured breast implant or textured tissue expander, you may be entitled to compensation under the MDL litigation process or via settlement.
Please contact Stark & Stark to speak to an Allergan lawsuit attorney, free of charge, who can help assess any claims that you may have and to help you understand the Allergan textured breast implant and textured tissue expander settlement and lawsuit process.
Stark & Stark Attorneys Recognized as New Jersey “Super Lawyers” and “Rising Stars” in 2026
Stark & Stark is pleased to announce that 15 of its attorneys have been selected for inclusion in the list of 2026 New Jersey Super Lawyers,...Bruce Stern, Esq. Secures $1,000,000 Settlement in Motor Vehicle Collision Case
Bruce Stern, Esq. recently secured a $1,000,000 settlement in a motor vehicle collision case.* “This case highlights how quickly things can go...Deborah Dunn, Esq. Elected to Board of Directors for Angel Flight East
Stark & Stark is pleased to announce that Deborah Dunn, Esq., Shareholder and Civil Trial Attorney, has been elected to the Board of Directors...Michael Jordan, Esq. Joins the Board of the Lawrence Township Community Foundation
It is our pleasure to announce that Michael Jordan, Esq. has joined the board of the Lawrence Township Community Foundation, an organization...Joseph Lemkin, Esq. Named to ROI-NJ Influencers: Power List 2026 – Law
Stark & Stark is proud to share that Joseph Lemkin, Esq., Shareholder, has been named to the 2026 Influencers: Power List in the Law category...Joseph Cullen, Esq. and Nicole Durso, Esq. Secure $2,000,000 Settlement in Personal Injury Matter
Joseph Cullen, Esq. and Nicole Durso, Esq. recently secured a $2,000,000 settlement in a personal injury matter involving a pedestrian who was struck...James Creegan, Esq. Appointed to Board of The 200 Club of Mercer County
It is our pleasure to announce that James Creegan, Esq. has been appointed to the Board of Directors of The 200 Club of Mercer County, an...